Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 3 of 3330
Next
>>
>
51 to 75 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		0.0107	uM	9047.132	0.8736	0.6481	0.6985
184A1	NM	Basal	5-FU	TYMS	TYMS	769	uM	9047.017	0.1559	-0.7788	0.8440
184A1	NM	Basal	5-FU	TYMS	TYMS	19200	uM	9047.017	0.1196	-0.8384	0.8440
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.000171	uM	12509.165	0.9871	0.9828	1.5022
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		6.67	uM	9047.132	0.8373	0.5511	0.6985
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.533	uM	12509.165	0.3318	-0.0404	1.5022
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	0.107	uM	12509.165	0.3373	-0.0298	1.5022
184A1	NM	Basal	AS-252424	PI3K	PI3K	0.0000853	uM	12509.165	1.0144	1.0191	1.5022
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	13.3	uM	12509.165	0.0484	-0.7335	1.5022
184A1	NM	Basal	AS-252424	PI3K	PI3K	0.0107	uM	12509.165	0.9308	0.9067	1.5022
184A1	NM	Basal	Afatinib	EGFR/HER2	ErbB	2.67	uM	12509.165	0.3136	-0.0757	1.5022
184A1	NM	Basal	AS-252424	PI3K	PI3K	0.267	uM	12509.165	0.8921	0.8536	1.5022
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		33.3	uM	9047.132	0.7816	0.4055	0.6985
184A1	NM	Basal	17-AAG	HSP90	HSP90	100	uM	9047.037	0.0825	-0.9826	0.5262
184A1	NM	Basal	5-DFUR	TYMS	TYMS	1.6	uM	12509.143	1.0174	1.0259	1.3392
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.16	uM	9047.037	0.4280	-0.6013	0.5262
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		0.0533	uM	9047.132	0.9788	0.9394	0.6985
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.000256	uM	9047.037	0.9096	0.6705	0.5262
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.0064	uM	9047.037	0.9396	0.7765	0.5262
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.00128	uM	9047.037	1.0758	1.2981	0.5262
184A1	NM	Basal	(Z)-4-Hydroxytamoxifen	ESR1		167	uM	9047.132	0.9698	0.9141	0.6985
184A1	NM	Basal	17-AAG	HSP90	HSP90	4	uM	9047.037	0.4226	-0.6108	0.5262
184A1	NM	Basal	17-AAG	HSP90	HSP90	0.8	uM	9047.037	0.4311	-0.5959	0.5262
184A1	NM	Basal	Baicalein	Lipoxygenase	Metabolism	0.0107	uM	5895.073	1.0510	1.0702	1.4431
184A1	NM	Basal	Baicalein	Lipoxygenase	Metabolism	0.00213	uM	5895.073	1.0337	1.0465	1.4431

|<
<<
Previous
Page 3 of 3330
Next
>>
>
51 to 75 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)